Company: AGIO
Filing Date: 2025-02-13
Form Type: 10-K
Source: 0001439222-25-000009
Chunk: 855

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-02-13
Form: 10-K
Item: Item 12
Chunk 855
---
 to PSUs with performance-based vesting criteria that are considered probable of achievement that we expect to recognize. There was $11.0 million of total unrecognized compensation expense related to PSUs 

F-21

with performance-based vesting criteria that are considered not probable of achievement.Market-based stock unitsWe have issued certain equity awards that contain market based vesting conditions, in which shares of stock are earned at vesting based on stock price performance. The fair value of market-based stock units, or MSUs, are estimated using a Monte Carlo simulation model. Assumptions and estimates utilized in the model include the risk-free interest rate, dividend yield, expected stock volatility and the estimated period to achievement of the market condition. The following table presents MSU activity for the year ended December 31, 2024:Number ofStock UnitsWeighted-AverageGrant DateFair ValueUnvested shares at December 31, 202342,695 $41.50 Expired(42,695)41.50 Unvested shares at December 31, 2024— $— As of December 31, 2024, there was no remaining unrecognized compensation expense related to MSUs.Amended and Restated 2013 Employee Stock Purchase PlanIn June 2013, our Board of Directors adopted, and in July 2013 our stockholders approved, the 2013 ESPP, which was further amended and restated by our Board of Directors in December 2024. We issued 102,805 shares and 112,832 shares during the years ended December 31, 2024 and 2023, respectively, under the 2013 ESPP. The 2013 ESPP provides participating employees with the opportunity to purchase up to an aggregate of 2,363,636 shares of our common stock. As of December 31, 2024, we had 1,583,234 shares available for future issuance under the 2013 ESPP. Stock-based compensation expenseDuring the years ended December 31, 2024, 2023 and 2022, we recorded stock-based compensation expense for employee and non-employee stock options, RSUs, PSUs, and ESPP shares. Stock-based compensation expense by award type included within the consolidated statements of operations is as follows:(In thousands)202420232022Stock options$17,519 $17,163 $23,731 Restricted stock units23,553 19,367